The journal Neuromuscular Disease has published a summary of the FSHD Society’s 2023 scientific conference held in Milan, Italy, this past June. The article was co-authored by Jamshid Arjomand, PhD,… Read More »
2023 International Research Congress summary
A holistic approach
What the FSHD Society can and must do for the community by June Kinoshita, FSHD Society The FSHD Society has been tightly focused on understanding FSHD and speeding up the… Read More »
Orphan drug designation for Epic Bio’s FSHD candidate
Read the full news release here. SOUTH SAN FRANCISCO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) — Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas… Read More »
Avidity Announces New Positive AOC 1001 Data
Avidity Biosciences, Inc. (Nasdaq: RNA), has announced new positive AOC 1001 data demonstrating improvement in multiple functional endpoints and favorable long-term safety and tolerability in people living with myotonic dystrophy… Read More »
The FSHD Society Celebrates Fulcrum’s Milestone in the Fight Against FSHD
Fulcrum Therapeutics has announced successful completion of patient enrollment in REACH Phase 3 trial The FSHD Society is thrilled to announce a significant milestone in the battle against FSHD. Fulcrum… Read More »